

SHORT BIO

Dr. Reggiani is a Neuropharmacologist by training with more than 30 year experience in drug discovery in leading pharmaceutical companies such as GSK, Schering Plough and Merck. In 2009, he joined the department of Drug Discovery at the Italian Institute of Technology (IIT) and in 2016 he has been appointed PI/Director of the D3 validation research line.

Dr Reggiani main research interests are stroke, neurodegeneration, pain, neurodevelopmental and psychiatric disorders. In his professional career, Dr Reggiani has brought to exploratory development 7 new compounds of which at least 3 reached phase III clinical phase. He holds 6 issued patents and has published approximately 100 original papers in leading peer reviewed journals.

Since 2003, Dr Reggiani is adjunct Professor of Pharmacological Biotechnology at the University Vita e Salute, San Raffaele Biomedical Science Park, Milan, Italy, and since 2004 he acts as an independent expert to assist the European Commission in the evaluation of research proposals related to calls in the Bioscience and Biomedical Area (theme Health) within the 6th and 7th European framework programs and Horizon 2020.

In 2016, Dr Reggiani has been named by the Ministry of Defense (Mr P.Gentiloni) and appointed by the Ministry of Health (Mrs B. Lorenzin) member of the Scientific Committee of the Istituto Superiore di Sanità. In Nov 2017, he has been granted the habilitation as a Full Professor of pharmacology (SSD:BIO/14) by the Italian Ministry of Education, University and Research (MIUR).

Dr Reggiani holds a doctoral degree in Chemistry and Pharmaceutical Technology and a postgraduate degree in Experimental Pharmacology from the University of Milan. He did his postdoctoral training in Neuropharmacology at the Dept of Pharmacological Sciences, Univ of Milan and at the Dept. of Pharmacology, Univ. of Texas, Medical School at Houston,USA.